{"id":5715,"date":"2021-11-30T09:00:00","date_gmt":"2021-11-30T08:00:00","guid":{"rendered":"https:\/\/preview.lifescience-factory.com\/community\/"},"modified":"2025-04-11T09:34:02","modified_gmt":"2025-04-11T07:34:02","slug":"community","status":"publish","type":"page","link":"https:\/\/preview.lifescience-factory.com\/en\/community\/","title":{"rendered":"Community"},"content":{"rendered":"\n\n
\n\n \n
\n <\/a>\n <\/div>\n\n \n
<\/div>\n\n \n \n
\n \"background\"\n\n \"background\"\n \n \n <\/div>\n \n \n
\n\n
\n\n \n
\n

\n Meet our network <\/h1>\n <\/div>\n\n \n
\n\n \n

When you join our curated community you can meet and work with our network of thought leaders, innovators, and industry experts. Our network is focused on entrepreneurship and the world of life science. The constant interaction across disciplines within this ecosystem stimulates new ways of thinking, producing solutions that redefine and vitalize our reality.<\/p>\n\n \n \n \n <\/div>\n <\/div>\n <\/div>\n\n<\/div>\n\n\n\n

\n\n
\n
\n
\n

meet our start-ups<\/h2>\n <\/div>\n <\/div>\n
\n
\n

Our diverse community of founders in the heart of G\u00f6ttingen is steadily growing. Read on to learn more about them \u2013 their stories, their successes, and their challenges. This is where entrepreneurship and scientific inquiry come together, enriching our collaborative community every day.<\/p>\n <\/div>\n <\/div>\n <\/div>\n \n

\n
\n
\n
\n

Maker’s Factory user<\/h4>\n

Digity<\/h2>\n <\/div>\n
\n

lab user<\/h4>\n

Cultimate Foods<\/h2>\n <\/div>\n
\n

Maker’s Factory user<\/h4>\n

Waterscope<\/h2>\n <\/div>\n
\n

lab user alumni<\/h4>\n

Ucaneo Biotech<\/h2>\n <\/div>\n
\n

lab user<\/h4>\n

Cinference<\/h2>\n <\/div>\n
\n

lab user<\/h4>\n

Curexsys GmbH \u2013 Pure to Cure<\/h2>\n <\/div>\n
\n

lab user<\/h4>\n

myotwin<\/h2>\n <\/div>\n
\n

lab user<\/h4>\n

Avocet Bio<\/h2>\n <\/div>\n
\n

lab user<\/h4>\n

BrainQR<\/h2>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n
\n
\n

Maker’s Factory user<\/h4>\n

Digity<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"Digity\n <\/div>\n
\n

Digity is a technology startup specializing on the hand with automated processes to equip the human hand with exoskeletons. Because our hands define how we interact with the world. Our mission is therefore to ensure that they are always healthy, protected and productive. Our patents and a digital background technology allow us to adapt our exoskeletons to different areas. Our startup product ARTUS addresses work safety and ergonomics of fingers in manual activities in industry and crafts. The interdisciplinary team from engineering, orthopedic technology and business administration emerged from an EXIST research transfer and wants to build a market leader from G\u00f6ttingen that offers real solutions for hand-related concerns.<\/p>\n\n \n \n <\/span>find out more<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n

lab user<\/h4>\n

Cultimate Foods<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"Cultimate\n <\/div>\n
\n

Cultimate Foods creates a game-changing ingredient based on cultivated fat in a sustainable and ethical way.
\nTheir unique solution enriches plant-based meat alternatives with authentic taste, mouthfeel, and texture. They believe that the future of meat is hybrid – a combination of plant-based proteins and their fat alternative product.<\/p>\n\n \n \n <\/span>Find out more<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n

Maker’s Factory user<\/h4>\n

Waterscope<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"\"\n\n <\/div>\n
\n

Globally, water-borne bacterial infections lead to half a million diarrhoeal-related deaths each year\u2014more than 2,000 deaths every day. This is more than malaria and HIV-related deaths combined. WaterScope seeks to overcome global water inequality by breaking barriers to reliable bacterial testing. The team has developed an innovative testing device that can reliably and automatically identify bacterial presence in water in as little as 18 hours. The testing data is provided in real time and is uploaded to a central dashboard, connecting users in over 165 countries around the world.<\/p>\n\n \n \n <\/span>Find out more<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n

lab user alumni<\/h4>\n

Ucaneo Biotech<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"Ucaneo\n <\/div>\n
\n

We are building the world’s first biotechnological Direct Air Capture (DAC) system with the goal to to capture 1% of the global CO2 emissions by 2035!<\/p>\n

Leveraging novel membranes and enzymes significantly reduces the energy consumption by lowering the conventional Direct Air Capture reaction temperature from up to 900\u00b0C to room temperature and avoiding active air intake. This enables massive cost savings and a sustainable reduction of CO2 in the atmosphere. <\/p>\n

Using the most modern equipment and S1 lab as well as our makerspace we found the perfect place at the Life Science Factory to develop our biotech hardware solution.<\/p>\n\n \n \n <\/span>find out more<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n

lab user<\/h4>\n

Cinference<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"Cinference\n <\/div>\n
\n

About 50% of all therapies have a protein component, but therapeutic protein development is very expensive and takes 2-3 years. Cinference is a life-science biotech startup that designs therapeutic proteins. Cinference’s mission is to shorten the protein development process to 1-2 months. To do this, the company uses data-efficient algorithms in combination with large AI models trained on millions of protein sequences to perform 99% of the design process digitally and optimize design parameters simultaneously. The young startup is on a growth trajectory and is hiring more biology talent to work on its first pharma partnerships. Cinference plans to move into the Life Science Factory next March and use the newly built lab.<\/p>\n\n \n \n <\/span>Find out more<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n

lab user<\/h4>\n

Curexsys GmbH \u2013 Pure to Cure<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"Curexsys\n <\/div>\n
\n

Curexsys is active in the anti-aging field and develops exosomes as innovative therapeutics to cure age-related diseases. <\/h3>\n

Curexsys is active in the anti-aging field and combats age-related defects with exosomes derived from induced mesenchymal stem cells (iMSCs).  Exosomes constitute a new therapeutic principle clearly distinct from classical small or large molecule compounds or cell therapy. They are small vesicles that are naturally released from a cell. They contain proteins, nucleic acids and metabolites, which carry information from secreting to receiving cells. Exosomes have immunomodulatory and anti-inflammatory effects.<\/p>\n

Due to increasingly aging societies, anti-aging therapies are of great interest to the pharma industry, health care providers and aging populations, and the Curexsys exosome platform will serve the arising demand of pure and functional exosomes in pharma industry. With the leading technology for highly selective and traceless purification of extracellular vesicles with low-affinity Fabs, Curexsys uses a unique technology to generate products for clinical applications, matching medical needs with increasing patient numbers in multiple disease areas.<\/p>\n\n \n \n <\/span>Find out more<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n

lab user<\/h4>\n

myotwin<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"Mytotwin\n <\/div>\n
\n

Redesigning drug development by continuous real-time & high-content analysis<\/h3>\n

The development and testing of new drugs through to approval are very cost-intensive. In addition, new regulatory provisions are intended to reduce the number of animal experiments in future. The biotech start-up myotwin uses stem cell-based heart muscle tissue in a specially developed measurement infrastructure. This allows a much earlier and comprehensive insight into the human reaction to an active ingredient. As a result, new active substances can be tested in preclinical trials without animal testing and safety in clinical trials can be increased. myotwin also uses its extensive data to create a digital twin of the human heart muscle in order to offer services in the field of predictive drug development in the future.<\/p>\n\n \n \n <\/span>Find out more<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n

lab user<\/h4>\n

Avocet Bio<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"Avocet\n <\/div>\n
\n

Pioneering novel RNA-based therapeutics<\/h3>\n

At Avocet Bio, our mission is clear: we want to break new ground by using our platform technology of RNA modulation as key therapeutic approach for a variety of diseases.<\/p>\n

As a biotech startup, we address some of the most pressing global health challenges, including respiratory viral infections, while expanding the potential of RNA modulation to other areas of medicine.<\/p>\n

Our long-term goal is to build a diverse portfolio of RNA-based therapeutics that address existing treatment gaps and offer new, more effective solutions for patients.<\/p>\n\n \n \n <\/span>Find out more<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n

lab user<\/h4>\n

BrainQR<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"\"\n\n <\/div>\n
\n

brainQr makes disordered proteins druggable<\/h3>\n

brainQr Therapeutics is developing next-generation therapies for major human diseases by targeting disordered proteins, a vast and previously largely undruggable class of biomolecules. Our mission is to harness cutting-edge scientific innovation to pioneer novel treatment strategies that address urgent unmet medical needs.<\/p>\n\n \n \n <\/span>Find out more<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n\n<\/div>\n\n\n\n

\n\n\n
\n
\n

Join our Start-ups<\/h2>\n <\/div>\n <\/div>\n \n\n \n<\/div>\n\n\n\n
\n\n\n
\n
\n\n\n
\n\n\n
\n

GliTTher: Lab Head\/Platform Manager (100%)<\/span><\/h3>\n <\/div>\n \n \n
\n\n\n \n\n \n
\n

Job Title: <\/strong> Lab Head\/Platform Manager (100%)
\n Company: <\/strong> GliTTher Technologies
\n Location: <\/strong> G\u00f6ttingen, Niedersachsen, Germany
\n Start Date: <\/strong> April or August 2025<\/p>\n

About GliTTher <\/strong>
\nVisit their website<\/a>
\nGliTTher is an innovative start-up dedicated to advancing treatments and diagnostics for
\ncancer-initiating cells. Located in G\u00f6ttingen, Germany, we leverage a pioneering
\ntechnology platform to identify and develop new therapies targeting cancer-initiating cells.<\/p>\n

Role Summary <\/strong>
\nWe are seeking a dynamic Lab Head\/Platform Manager to lead our research efforts in
\nglioma-initiating cells. In this role, you will oversee the characterization of these cells,
\nutilizing FACS sorting and validating their stemness properties. Additionally, you will lead
\nthe screening for novel therapeutic compounds, advancing GliTTher\u2019s proprietary platform
\nto uncover potential new treatments for glioma.<\/p>\n

Key Responsibilities <\/strong>
\n\u2022 Lead the setup and management of GliTTher’s technology platform focused on
\nglioma-initiating cells
\n\u2022 Conduct FACS sorting and stemness validation of glioma-initiating cells
\n\u2022 Drive screening and testing of GliTTher-identified molecules as potential glioma
\ntreatments
\n\u2022 Manage laboratory operations, ensuring high standards of research quality and
\nintegrity<\/p>\n

Required Expertise <\/strong>
\n\u2022 Cellular Biology <\/strong> \u2013 Proficiency in cellular mechanisms and cancer biology
\n\u2022 Cancer Research <\/strong> \u2013 Solid background in cancer research methodologies
\n\u2022 Flow Cytometry <\/strong> \u2013 Strong experience in FACS sorting and data interpretation<\/p>\n

Technical Skills <\/strong>
\n\u2022 Primary cell culture
\n\u2022 Flow cytometry
\n\u2022 Microscopy
\n\u2022 Cloning
\n\u2022 Molecular biology techniques
\n\u2022 Inhibitor testing<\/p>\n

Application Deadline <\/strong>
\nSubmit your CV and a statement of motivation by March 31, 2025 <\/strong> . Please email your
\napplication to sammy@glitther.com<\/a> and virginie@glitther.com<\/a><\/p>\n <\/div>\n \n\n \n \n \n\n \n \n\n \n\n <\/div>\n \n\n <\/div>\n\n\n <\/div>\n <\/div>\n\n\n<\/div>\n\n\n\n

\n \n
\n
\n\n
<\/div>\n \n <\/div>\n\n \n <\/div>\n\n<\/div>\n\n\n\n
\n\n
\n
\n
\n

get in touch with our mentors<\/h2>\n <\/div>\n <\/div>\n
\n
\n

Get expert support from our mentors and investors. Especially in the early stages, start-ups need tailored support in meeting their challenges. Our experts are successful life science founders, investors, and scientists who are always eager to share their specific expertise to sustainably boost innovative projects. <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n \n<\/div>\n\n\n\n

\n\n \n\n
\n\n \n \n
\n\n\n
\n \n \"\"\n\n <\/a>\n <\/div>\n \n\n

Dr. Grit Zahn<\/h3>\n \n\n

Head of Research at Eternygen GmbH I Drug Development, Company building, technology transfer<\/h5>\n \n\n

Grit is a biochemist and has been active in drug development for more than 20 years. She has held a number of positions at many institutions and companies, working as a researcher at the Charit\u00e9 university medical center in Berlin; in drug development at the Jerini AG biotech company where she helped develop a product to market maturity; in technology transfer at ipal GmbH; and today at Eternygen GmbH, where she is head of research and also advises other biotech companies.<\/p>\n\n\n <\/span>LinkedIn Profil Grit Zahn<\/span><\/a>\n \n <\/div>\n \n

\n\n\n
\n \n \"\"\n\n <\/a>\n <\/div>\n \n\n

Julia Schomburg<\/h3>\n \n\n

Investment Manager at Arkadien Finanz I Investor Readiness, Business Structure, Team Development<\/h5>\n \n\n

Julia Schomburg is a communication economist with several years of experience in advertising agencies. For over 15 years now, she has played a key role as an Investment Manager at Arkadien Finanz. Drawing on her extensive insights into a wide range of industries and companies, she supports startups primarily in the areas of investor readiness, business structure, and team development.<\/span><\/p>\n\n\n <\/span>LinkedIn Profil Julia Schomburg<\/span><\/a>\n \n <\/div>\n \n

\n\n\n
\n \n \"\"\n\n <\/a>\n <\/div>\n \n\n

Daniel Schuppmann<\/h3>\n \n\n

Lawyer for IP & Tech Law at NEUWERK I Life Sciences, Licensing, Product Development Support<\/h5>\n \n\n

Daniel is a lawyer advising on all aspects of intellectual property and technology law, data protection as well as contractual matters with a focus on helping life science companies with the protection and licensing of their technologies and providing legal support throughout the whole life circle of product development.<\/span><\/p>\n\n\n <\/span>LinkedIn Profil Daniel Schuppmann<\/span><\/a>\n \n <\/div>\n <\/div>\n \n\n<\/div>\n\n\n\n\n

\n
\n\n
\n\n
\n\n
\n

learn more?<\/h2>\n <\/div>\n\n
\n

Then sign up for a community ticket and get access to the entire network.<\/p>\n <\/div>\n\n

\n <\/span>Angebot<\/span><\/a>\n <\/div>\n\n <\/div>\n\n <\/div>\n\n <\/div>\n<\/div>\n\n\n\n\n\n\n
\n\n
\n
\n

shoutout to our partners!<\/h2>\n <\/div>\n <\/div>\n \n
\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n <\/div>\n \n<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":34,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-5715","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/preview.lifescience-factory.com\/en\/wp-json\/wp\/v2\/pages\/5715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/preview.lifescience-factory.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/preview.lifescience-factory.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/preview.lifescience-factory.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/preview.lifescience-factory.com\/en\/wp-json\/wp\/v2\/comments?post=5715"}],"version-history":[{"count":129,"href":"https:\/\/preview.lifescience-factory.com\/en\/wp-json\/wp\/v2\/pages\/5715\/revisions"}],"predecessor-version":[{"id":56566,"href":"https:\/\/preview.lifescience-factory.com\/en\/wp-json\/wp\/v2\/pages\/5715\/revisions\/56566"}],"wp:attachment":[{"href":"https:\/\/preview.lifescience-factory.com\/en\/wp-json\/wp\/v2\/media?parent=5715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}